Suchergebnisse - "Lennox, Jeffrey L"

PubPharm (11)

1

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies : final results of two randomised, placebo-controlled trials

enthalten in: The Lancet. Infectious diseases | 2013

von Eron, J. | Cooper, D. | Steigbigel, R. | +116

CommentIn: Lancet Infect Dis. 2013 Jul;13(7):561-2. - PMID 23664332

2

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients : final 5-year results from STARTMRK

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2013

von Rockstroh, J. | DeJesus, E. | Lennox, J. | +80

3

A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients : a pilot randomized trial to assess efficacy and safety profile: the KITE study

enthalten in: AIDS research and human retroviruses | 2012

von Ofotokun, I. | Sheth, A. | Sanford, S. | +6

4

The use of HIV-1 integrase inhibitors in antiretroviral naive patients

enthalten in: Current opinion in HIV and AIDS | 2012

von Lennox, J.

5

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients : week-192 overall and subgroup analyses from STARTMRK

enthalten in: HIV clinical trials | 2012

von DeJesus, E. | Rockstroh, J. | Lennox, J. | +80

ErratumIn: HIV Clin Trials. 2012 Sep-Oct;13(5):preceding 233

6

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients : 156-week results from STARTMRK

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2011

von Rockstroh, J. | Lennox, J. | Dejesus, E. | +13

7

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients : 96-week efficacy, durability, subgroup, safety, and metabolic analyses

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2010

von Lennox, J. | Dejesus, E. | Berger, D. | +82

ErratumIn: J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e120 Dosage error in article text

8

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection : week 96 results of the BENCHMRK 1 and 2 Phase III trials

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2010

von Steigbigel, R. | Cooper, D. | Teppler, H. | +120

9

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection : a multicentre, double-blind randomised controlled trial

enthalten in: Lancet (London, England) | 2009

von Lennox, J. | DeJesus, E. | Lazzarin, A. | +81

ErratumIn: Lancet. 2009 Dec 19-2010 Jan 1;374(9707):2054

10

Raltegravir with optimized background therapy for resistant HIV-1 infection

enthalten in: The New England journal of medicine | 2008

von Steigbigel, R. | Cooper, D. | Kumar, P. | +127

CommentIn: N Engl J Med. 2008 Jul 24;359(4):416-8. - PMID 18650518